Hearts & Minds Blog

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density… more

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

Tim Mayleben

President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the… more

Posted In: Industry Insights

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than… more

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

Tim Mayleben

President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since… more

Posted In: Company News

Going with Your Gut

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Sometimes in science, you have to go with your gut. Years ago, my gut instinct told me that a drug… more